Drug manufacturer Novartis this afternoon significantly beefed up its conditions on 340B pricing for hospitals.
Two others—GlaxoSmithKline and Pfizer—made similar moves on Friday. Novartis is the sixth to stiffen its 340B pricing policy since a federal appeals court ruled in late January “that “Congress never said that drug makers must deliver discounted Section 340B drugs to an unlimited number of contract pharmacies.”
Drug manufacturer Novartis this afternoon significantly beefed up its conditions on 340B pricing for hospitals. Two others—GlaxoSmithKline and Pfizer—made similar moves on Friday. Novartis is the sixth to stiffen its 340B pricing policy since a federal appeals court ruled in […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
